妇科肿瘤学中的预先授权:临床影响分析
该回顾性横断面研究分析了宾夕法尼亚大学妇科肿瘤诊所2021年1月至3月的2112次就诊,发现5%的就诊期间经历预先授权,另有20%的患者在更早的癌症治疗中面临预先授权请求。83项请求中影像学占54%,支持性药物占29%,化疗占17%;申诉后79%获批,从下单到服务平均延迟16天(95%CI 11-20,范围0-98天)。17项拒绝中3项(18%)导致治疗计划重大改变。作者认为需要改革以减少肿瘤学中预先授权的负担。
要点
- 25%的妇科肿瘤患者在癌症治疗过程中经历过预先授权。
- 申诉后79%的预先授权请求最终获批,但平均延迟16天(95%CI 11-20)。
- 17项拒绝中3项(18%)导致未接受计划治疗等重大改变。
核心结论
- 25%的妇科肿瘤患者在癌症治疗过程中经历过预先授权;80%的申请最终获批,但出现预先授权时患者经历超过2周的护理延迟;作者认为需要改革以减少肿瘤学中预先授权的负担。
研究设计与样本
- 回顾性横断面研究,纳入2021年1月至3月在宾夕法尼亚大学妇科肿瘤诊所就诊的1406名独特患者的2112次就诊。
主要发现
- 2112次就诊中5%在3个月研究期间经历预先授权,另有20%在更早的癌症治疗中面临预先授权请求。
- 83项预先授权请求中影像学占54%,支持性药物占29%,化疗占17%。
- 申诉后79%的病例获批;获批病例从下单到服务平均16天(95%CI 11-20,范围0-98天)。
- 17项拒绝中3项(18%)导致重大治疗改变(即未接受计划治疗)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Prior authorization was designed to minimize unnecessary care and reduce spending but has been associated with delays in necessary care. Our objective was to estimate the occurrence of prior authorization, and impact on cancer care, in gynecologic oncology. METHODS: We performed a retrospective cross-sectional study of patients seen in University of Pennsylvania gynecologic oncology practices (January-March 2021). Using electronic medical records, we measured the incidence of prior authorization during the 3-month period and prior experience of prior authorization for cancer care overall and by type of order (chemotherapy, imaging, surgery, prescription drugs). We assessed the impact of prior authorization occurrence on clinical outcomes (time to service, changes in care). RESULTS: Of the 2112 clinic visits of 1406 unique patients, 5% experienced prior authorization during the 3-month study period. An additional 20% faced prior authorization requests earlier in cancer care. Of the 83 prior authorization requests, imaging accounted for the majority (54%) followed by supportive medications (29%) and chemotherapy (17%). After appeal, 79% of cases were approved. For patients whose prior authorizations were approved, there was a mean of 16 days from order placement to care delivery (95% CI 11-20, range 0-98 days). Of the 17 denials, 3 (18%) led to a substantial change in care (i.e., not receiving planned treatment). CONCLUSION: 25% of gynecologic oncology patients experienced prior authorization during their cancer care. While 80% of claims were ultimately approved, patients experienced over a 2-week delay in care when prior authorization occurred. Reform is needed to reduce the burden of prior authorization in oncology.
引用
- Smith AJB, Mulugeta-Gordon L, Pena D, et al. Prior authorization in gynecologic oncology: An analysis of clinical impact. Gynecol Oncol. 2022. PMID: 36244827. doi:10.1016/j.ygyno.2022.10.002
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。